Tyrvaya is a prescription nasal spray approved by the FDA in October 2021 to treat dry eye disease in adults. It’s the first nasal spray of its kind. Unlike eye drops, it stimulates the body’s own tear glands through a nerve pathway in the nose.
Varenicline, the active ingredient, activates nicotinic receptors in the nasal cavity and triggers the trigeminal parasympathetic pathway. Clinical trials ONSET-1 and ONSET-2 confirmed significant increases in natural tear production at week four. Patients report relief from burning, stinging, and chronic dryness. The main side effect is sneezing. It affects 82% of users. Monthly cost without insurance runs $600 to $700 (USD).
This review covers how Tyrvaya works, what patients actually experience, how it compares to Restasis and Xiidra, and whether the price makes sense. Read on to find out if Tyrvaya is the right fit for your dry eye treatment plan.
What Is Tyrvaya?
Tyrvaya is a prescription nasal spray approved by the FDA in October 2021 for the treatment of dry eye disease. The active ingredient is varenicline solution 0.03 mg per spray. Here’s the surprising part: despite treating eye disease, Tyrvaya is administered through the nose, not the eyes.
Viatris manufactures and markets Tyrvaya under an exclusive license from Oyster Point Pharma. The product targets adults diagnosed with dry eye disease, a chronic condition affecting tens of millions of people in the US.
In fact, Tyrvaya’s biggest selling point is its different mechanism. It targets the underlying nerve pathway rather than coating the eye surface with artificial lubricants. The result? The body’s own tear-production system does the work.
Is Tyrvaya a Nasal Spray or Eye Drops?
Tyrvaya is a nasal spray, not an eye drop, despite being prescribed to treat dry eye disease. It’s delivered as one spray into each nostril twice daily. This surprises most patients who expect drops applied directly to the eye.
Here’s why the nose matters: the nasal route gives varenicline access to the trigeminal parasympathetic pathway, a nerve network running from the nose to the lacrimal glands. Eye drops can’t reach this pathway because they act on the eye surface only.
Patients use Tyrvaya by inserting the device just inside the nostril and pressing the plunger. One spray per nostril, morning and evening. That’s the entire routine.
What Condition Does Tyrvaya Treat?
Tyrvaya treats the signs and symptoms of dry eye disease, a chronic inflammatory condition affecting tear film quality. The FDA approved it specifically for this indication following two successful pivotal clinical trials called ONSET-1 and ONSET-2. So it’s not experimental. It’s fully backed by clinical evidence.
Dry eye disease occurs when the eyes don’t produce enough tears or when tear quality is poor. Symptoms include burning, stinging, redness, blurred vision, and a foreign-body sensation. For many patients, these symptoms are daily and debilitating.
Tyrvaya is a prescription-only treatment. Patients require a diagnosis and a valid prescription from a licensed eye care provider. The drug isn’t approved for any other condition and doesn’t replace regular eye care visits.
How Does Tyrvaya Work?
Tyrvaya works by activating nicotinic acetylcholine receptors in the nasal cavity, which stimulates the trigeminal parasympathetic pathway to trigger natural tear production. Varenicline binds to receptors in the nose and sends a nerve signal to the lacrimal gland. The signal prompts the lacrimal gland to secrete tears. Think of it this way: the nose becomes the remote control for the tear glands.
The trigeminal nerve connects the nasal mucosa to the lacrimal functional unit, which includes the lacrimal gland, meibomian glands, and goblet cells. Stimulating this pathway promotes production of all three layers of the tear film: aqueous, lipid, and mucin components.
This is where it gets interesting. Artificial tears replace tears temporarily. Tyrvaya activates the biological process that generates real tears from the lacrimal gland itself. The result is a more physiologically complete tear film that the body produces on its own.
Does Tyrvaya Stimulate Natural Tear Production?
Yes. Tyrvaya directly stimulates natural tear production by targeting nicotinic acetylcholine receptors in the nose, not by adding lubricants to the eye. Clinical trial data from ONSET-1 and ONSET-2 confirmed a statistically significant increase in tear production measured by the Schirmer test at week four.
Here’s what the numbers say: in the ONSET-1 trial, 47.1% of patients treated with Tyrvaya 0.03 mg achieved a 10 mm or greater increase in Schirmer score at week four. The vehicle control group? Only 20.3%. That’s more than double the response rate.
The Schirmer test measures tear production by placing a small strip under the lower eyelid and recording how far tears travel in five minutes (0 to 35 mm scale). An increase of 10 mm or greater is considered clinically meaningful. Tyrvaya delivered that result for nearly half of treated patients.
What Are the Ingredients in Tyrvaya?
Tyrvaya contains varenicline as its active ingredient at a concentration of 0.03 mg per 0.05 mL spray, which is significantly lower than the varenicline dose used in smoking cessation therapy. Each unit-dose vial delivers one spray and is discarded after single use. That single-use design keeps the product sterile without preservatives that can irritate the nose or eyes.
The inactive ingredients include sodium chloride, boric acid, mannitol, edetate disodium, citric acid, sodium citrate, and water for injection. These excipients stabilize the varenicline solution and maintain the correct pH for nasal delivery.
Now here’s the thing most patients ask about: Tyrvaya’s dose is approximately 16 to 33 times lower than the doses used in Chantix for smoking cessation. The FDA label for Tyrvaya does not carry the same black-box psychiatric warning as Chantix. Different dose, different risk profile.
Key Ingredients:
- Varenicline 0.03 mg per spray (active ingredient)
- Sodium chloride (tonicity agent)
- Boric acid and sodium citrate (buffering agents)
- Mannitol (stabilizer)
- Edetate disodium (chelating agent)
- Water for injection (vehicle)
What Are the Benefits of Tyrvaya?
Tyrvaya offers a non-eye-drop approach to dry eye treatment. The treatment stimulates natural tear production through a nasal pathway rather than adding artificial lubricants to the eye surface. For patients who dislike instilling drops, struggle with proper drop technique, or experience burning from preservative-containing products, this delivery method is a genuine alternative. Clinical evidence supports meaningful tear production increases within four weeks.
The treatment produces all three layers of the natural tear film: aqueous, lipid, and mucin. Artificial tears typically supplement only the aqueous layer. A more complete tear film addresses a broader range of dry eye symptoms and may provide longer-lasting relief between doses.
And here’s the practical benefit: Tyrvaya is administered only twice daily, morning and evening. Many patients using artificial tears apply drops six to eight times per day. The lower dosing frequency improves adherence and reduces treatment burden for patients managing chronic dry eye alongside other daily medications.
Does Tyrvaya Actually Relieve Dry Eye Symptoms?
Yes. Tyrvaya significantly reduces dry eye symptoms in clinical trials, with the ONSET-1 and ONSET-2 studies demonstrating both objective tear production increases and subjective symptom improvements. Patients reported meaningful improvements in dryness, burning, and overall eye discomfort scores over the four-week treatment period. The results aren’t anecdotal. They’re statistically confirmed.
The Eye Dryness Score, a patient-reported outcome measured on a 0 to 100 visual analog scale, showed greater improvement in Tyrvaya-treated patients compared to vehicle controls. Lower scores indicate less dryness. The difference between groups reached statistical significance in both pivotal trials.
Real-world patient feedback echoes the clinical data. Many users report noticeable relief within the first one to two weeks of consistent twice-daily use. Maximum benefit is typically observed after four to six weeks of continuous treatment.
How Quickly Does Tyrvaya Work?
Tyrvaya begins producing measurable increases in tear production within the first week of use, with full clinical benefit typically observed by week four of twice-daily dosing. The prescribing information and clinical trial data support a four-week assessment point for evaluating treatment response. Don’t stop early based on lack of response in the first few days. That’s not enough time.
Some patients notice symptomatic relief, such as reduced burning or dryness, within the first two weeks. Others experience a gradual improvement across the full four-week period. Consistent twice-daily dosing in both nostrils is essential to maintain the nerve stimulation needed for sustained tear production.
Here’s the part most people miss: Tyrvaya doesn’t provide immediate on-demand relief the way artificial tears do. It works through a pharmacological mechanism that requires regular dosing to sustain the nerve pathway activation. It’s a treatment, not a rescue drop. Patients expecting instant relief should discuss realistic timelines with their physician before starting.
What Do Tyrvaya Reviews Say?
Tyrvaya receives mixed reviews from patients, with many reporting meaningful relief from chronic dry eye symptoms while others cite side effects, cost barriers, and insurance coverage difficulties as major concerns. On major drug review platforms, Tyrvaya scores range from 3.5 to 4.2 out of 5. It’s not universally loved, but the patients who respond well tend to be enthusiastic.
The most consistently positive feedback centers on the novel delivery method, the reduction in overall eye drop use, and improvement in chronic dryness that didn’t respond to artificial tears alone. Patients with moderate to severe dry eye disease tend to report the highest satisfaction rates.
Negative reviews? They frequently mention the sneezing side effect, the learning curve with the nasal applicator, and the high out-of-pocket cost when insurance doesn’t cover it. Some patients also report minimal benefit, particularly when dry eye has an underlying cause not addressed by increased tear production.
What Are the Positive Experiences With Tyrvaya?
Tyrvaya users who respond well report significant reductions in burning, stinging, and the foreign-body sensation associated with dry eye disease after two to four weeks of consistent use. Many reviewers note that Tyrvaya allowed them to reduce or eliminate daily artificial tear use entirely. Screen-intensive workers and contact lens wearers report disproportionately high satisfaction rates.
Here’s what stands out in the positive reviews: several patients with severe chronic dry eye describe Tyrvaya as the first treatment to provide meaningful relief after years of unsuccessful therapy. Lubricating drops, warm compresses, omega-3 supplements. Nothing worked. Then Tyrvaya. These patients consistently emphasize sticking with the treatment through the initial adjustment period.
The twice-daily dosing schedule receives consistent praise for fitting naturally into morning and evening routines. Patients who struggled with remembering multiple daily eye drop applications find the structured twice-daily nasal spray regimen easier to maintain over weeks and months.
What Are the Common Complaints About Tyrvaya?
The most common complaint about Tyrvaya is sneezing immediately after administration, which affects approximately 82% of users in clinical trials and persists throughout the treatment period for many patients. The sneezing typically resolves within minutes. But is that enough to tolerate it long term? For most patients, yes. For others, it’s a dealbreaker.
Cost ranks as the second most cited complaint. Without insurance coverage, Tyrvaya costs approximately $600 to $700 (USD) per month. Compare that to $15 to $40 per month for artificial tears and the gap is hard to ignore. Insurance formulary restrictions and prior authorization requirements create additional access barriers even for those with coverage.
Nasal irritation, cough, and throat irritation are also reported frequently. Some patients find the unit-dose applicator awkward to use consistently, particularly during the first few days. A small number of users report worsening nasal symptoms that prompted discontinuation.
What Are the Side Effects of Tyrvaya?
Tyrvaya causes sneezing as its most common side effect. Approximately 82% of patients in clinical trials experienced it, followed by cough (19%), throat irritation (13%), and nasal irritation (9%). These side effects directly reflect the stimulation of the nasal mucosa and the trigeminal parasympathetic pathway. In other words, the side effects are a byproduct of the mechanism that makes it work.
The good news? Sneezing typically occurs within seconds to minutes of nasal administration and resolves on its own. The sneezing doesn’t reduce the drug’s effectiveness, as enough varenicline absorbs into the nasal tissue before the sneeze occurs. Patients should administer both sprays before sneezing if possible.
Less common side effects include nasal congestion, rhinorrhea (runny nose), and watery eyes. Serious adverse reactions are rare and haven’t been identified as a significant concern in post-marketing surveillance. Patients experiencing persistent or severe nasal symptoms should consult their prescriber.
Side Effects by Frequency:
| Side Effect | Frequency in Trials | Severity |
|---|---|---|
| Sneezing | 82% | Mild to moderate |
| Cough | 19% | Mild |
| Throat irritation | 13% | Mild |
| Nasal irritation | 9% | Mild |
| Runny nose | Less common | Mild |
Who Should Avoid Tyrvaya?
Tyrvaya is contraindicated in patients with known hypersensitivity to varenicline or any inactive ingredient in the formulation, and the manufacturer advises caution in patients with active nasal obstruction or significant nasal disease. Patients who can’t breathe through the nose reliably may not absorb the medication consistently. Less absorption means less tear stimulation and reduced effectiveness.
Pregnant and breastfeeding patients should discuss Tyrvaya use with their physicians before starting. Adequate and well-controlled studies in pregnant women haven’t been conducted. The prescribing information recommends weighing benefits against potential risks for this population.
Patients taking other nicotinic receptor-active medications should inform their provider before starting Tyrvaya. Although the dose is very low, potential interactions with systemic nicotinic medications haven’t been fully characterized. Patients with a history of seizures should also discuss the decision carefully with their physician before beginning treatment.
Tyrvaya vs. Eye Drops: Which Is Better?
Tyrvaya and eye drops address dry eye disease through fundamentally different mechanisms. Direct comparison requires considering the patient’s specific diagnosis and symptom severity. Tyrvaya stimulates natural tear production via a nasal nerve pathway. Eye drops lubricate the eye surface temporarily. Prescription drops like Restasis and Xiidra target inflammation. Three different tools for three different approaches.
Artificial tears provide immediate symptom relief but don’t address the underlying tear production deficiency. They require frequent application, four to eight times daily for most products. Tyrvaya works gradually over weeks but trains the body to produce more natural tears continuously rather than relying on external lubrication.
Bottom line: when compared to other prescription dry eye treatments, Tyrvaya offers a distinct delivery advantage for patients who struggle with eye drop instillation. But Restasis and Xiidra have longer track records, broader insurance coverage, and established long-term safety data. Tyrvaya, approved in 2021, is still accumulating that evidence.
Tyrvaya vs. Competing Treatments:
| Treatment | Type | Mechanism | Typical Cost (USD/month) |
|---|---|---|---|
| Tyrvaya | Prescription nasal spray | Nerve stimulation | $600-700 |
| Restasis | Prescription eye drops | Anti-inflammatory | $400-500 |
| Xiidra | Prescription eye drops | Anti-inflammatory | $500-600 |
| Artificial tears | OTC eye drops | Lubrication | $15-40 |
Is Tyrvaya FDA Approved?
Yes. Tyrvaya received FDA approval on October 15, 2021. It became the first nasal spray approved by the FDA for the treatment of dry eye disease. The New Drug Application was reviewed under the standard review pathway. Approval was based on data from the ONSET-1 and ONSET-2 randomized, double-masked, vehicle-controlled trials. It’s not a new or untested drug.
The FDA-approved indication is specifically for the treatment of the signs and symptoms of dry eye disease in adults. The approval covers the 0.03 mg per 0.05 mL unit-dose formulation only. Off-label use in pediatric populations hasn’t been studied or approved.
FDA approval confirms that Tyrvaya met the agency’s standards for both safety and efficacy based on substantial clinical evidence. Oyster Point Pharma, the original developer, submitted the NDA with complete trial data, safety monitoring reports, and manufacturing quality documentation. That’s the full standard process.
How Much Does Tyrvaya Cost?
Tyrvaya costs approximately $600 to $700 (USD) per month without insurance coverage. The price places it among the more expensive prescription dry eye treatments currently available. The list price reflects the novel mechanism, single-use unit-dose packaging, and the research investment behind its FDA approval. Generic versions aren’t currently available.
Insurance coverage for Tyrvaya varies significantly by plan. Many commercial insurance plans list it on higher-cost tiers requiring prior authorization and step therapy documentation. That means patients may need to demonstrate failure of lower-cost alternatives first before coverage is approved. It’s a process that takes time and paperwork.
Here’s the good news: Viatris offers a savings program for eligible commercially insured patients, potentially reducing out-of-pocket costs substantially. Patients without insurance or with Medicare coverage may qualify for patient assistance programs. Checking the official manufacturer website for current savings card eligibility before filling the first prescription is strongly advisable.
Is Tyrvaya Worth the Price?
Tyrvaya is worth the price for patients with moderate to severe dry eye who haven’t achieved adequate relief from less expensive treatments and are covered by insurance with manageable copays. The cost-benefit calculation depends heavily on individual insurance coverage, symptom severity, and treatment response. Patients paying minimal copays consistently rate the value as positive.
For uninsured patients paying full price, the monthly cost of $600 to $700 (USD) makes long-term use financially challenging. Comparing this to $15 to $40 per month for artificial tears highlights the significant cost gap. Patients in this situation benefit from discussing formulary alternatives with their provider before committing to Tyrvaya.
The novel delivery mechanism, twice-daily dosing convenience, and clinical evidence of natural tear production increases justify the premium price for the right patient. Those with documented aqueous-deficient dry eye who have exhausted OTC options represent the strongest candidates for Tyrvaya’s value proposition.
Where Can You Buy Tyrvaya?
Tyrvaya is available by prescription only at licensed US pharmacies, including major retail chains such as CVS, Walgreens, Rite Aid, and Walmart Pharmacy, as well as mail-order and specialty pharmacies. A valid prescription from a licensed eye care provider is required. Tyrvaya isn’t sold over the counter and isn’t available without a prescription.
Mail-order pharmacy services may offer cost savings for patients on long-term treatment. Many insurance plans require or incentivize mail-order delivery for maintenance medications, which can reduce per-dose cost and eliminate monthly pharmacy trips for ongoing users.
Specialty pharmacies affiliated with ophthalmology practices sometimes stock Tyrvaya directly. Patients can fill their prescription at the same location as their eye care appointment. Online pharmacies operating within US regulatory frameworks also dispense Tyrvaya with a valid prescription uploaded or transferred from a provider.
Is Tyrvaya Worth It?
Tyrvaya is worth considering for adults with chronic dry eye disease who haven’t found adequate relief from artificial tears and prefer a non-eye-drop delivery method, particularly when insurance coverage reduces out-of-pocket cost. The FDA-approved mechanism, clinical trial evidence, and unique nasal delivery route set it apart from other prescription options. The main obstacles are cost and the sneezing side effect. Both are manageable for the right patient.
Patients with mild dry eye adequately managed with over-the-counter lubricating drops are unlikely to need Tyrvaya’s prescription-grade intervention. The cost differential is significant, and the sneezing side effect makes twice-daily use socially awkward for some individuals. A thorough discussion with an eye care provider is the best first step before starting treatment.
For the right patient, Tyrvaya represents a genuine advance in dry eye therapy. The ability to produce natural, physiologically complete tears through a nasal spray is a novel approach with meaningful clinical backing. Patients who have struggled with chronic dry eye and exhausted simpler options deserve to know this option exists as a medically supported alternative.